FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial Hélène BellioNicolas RoussotAurélie BertautAlice HervieuSylvie ZanettaZoe TharinJulie VincentLeila BengrineAudrey HennequinJean-Florian GuionAxelle BoudrantThomas CollotFrancois G...
Methods: The FOLFIRINOX-R trial was a phase 1/2 study where the dose-escalation part (3 + 3 design with three dose levels, DLs) was completed before its early termination. FOLFIRINOX (14-day cycle) included oxaliplatin (standard dose), folinic acid, fluorouracil and irinotecan (150 or 180...
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. 来自 Semantic Scholar 喜欢 0 阅读量: 64 作者: E Assenat,F Desseigne,S Thezenas,F Viret,L Mineur,A Kramar,E Samalin,F Portales,F Bibeau,E Crapez-Lopez 展开 ...
multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic canc...
[12] CONROY T, BOSSET J F, ETIENNE P L, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised,...
This multicenter, randomized (1:1), open-label, phase II trial will assess and compare the effectiveness and toxicity of mFOLFIRINOX and mFOLFOX 6 in patients with high-risk stage III colon cancer after radical resection. The goal of the trial is to enroll 312 eligible patients, from 11 in...
Meaning These findings suggest that NALIRIFOX and FOLFIRINOX may provide equal efficacy as first-line treatment of metastatic pancreatic cancer, but with different toxicity profiles. Abstract Importance The NAPOLI 3 trial showed the superiority of fluorouracil, leucovorin, liposomal irinotecan, and oxalipla...
16. Marijnen CAM, Nagtegaal ID, Kapiteijn E, et al; Cooperative investigators of the Dutch Colorectal Cancer Group. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55(5):131...
Perkhofer L, Berger AW, Beutel AK et al (2019) Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study. BMC Cancer 19(1)...
The Canady Helios Cold Plasma System (CHCPS) paired with the Canady Helios Cold Plasma Scalpel has potential as an anti-cancer therapy (U.S. Patent No. 9999462)30. The CHCPS is currently subject to a phase I FDA Investigational Device Exemption Approval clinical trial in the United States ...